한미약품 사태와 바이오제약주에 대한 영향력, 추후 바이오제약 산업의 전망
- 최초 등록일
- 2016.11.20
- 최종 저작일
- 2016.11
- 14페이지/ MS 워드
- 가격 2,500원
목차
Ⅰ. What is Hanmi pharmaceutical corporation.,Ltd. crisis?
Ⅱ. Influence of Hanmi pharmaceutical corporation.,Ltd. Crisis.
1. Influence on bio-pharmaceutical business.
1) Positive Influences
2) Negative Influences
2. Current policies and change of policy anticipated.
1) Current policies
2) Weaknesses of current policies and change of policy anticipated
Ⅲ. Expected outlook of the industry.
본문내용
Ⅰ. What is Hanmi pharmaceutical corporation.,Ltd. crisis?
On September 29, 2016 after stock market closed, Hanmi pharmaceutical
corporation.,Ltd. announced that they had signed a contract to export their technology regarding anti-cancer medicine to an American medical company, Genentech, and was expecting revenue of approximately 1,000,000,000,000 Korean Won. On the same day, they received information about rescission of export contract of license Olita Tab (Treatment for lung cancer) from medical company Boehringer Ingelheim, but did not announce the bad news. The next day, as the export announcement was appealing to many investors, they rushed to the stock market and bought Hanmi pharmaceutical corporation.,Ltd. stocks as the market opened at 09:00. The price went up by 5% in the first 29 minutes. However, when Hanmi pharmaceutical corporation.,Ltd. announced that the export contract of license from medical company Boehringer Ingelheim was withdrawn at 09:29, the stock price dropped dramatically.
참고 자료
없음